

CMS ADVISES ON THE MORE THAN 100 MILLION ACQUISITION OF ADL BIOPHARMA

Posted on 17/05/2023



Category: [Deal & transactions](#)

Tags: [ADL Biopharma](#), [Aleksandra Czajka](#), [CMS Albiñana & Suárez de Lezo](#), [Elena Alcázar](#), [Luis Miguel de Dios](#), [Saphira Mouyazek](#), [sx3](#), [Wacker Group](#)



CMS Albiñana & Suárez de Lezo has advised the Wacker Group - whose parent company Wacker Chemie AG is listed on the Frankfurt Stock Exchange - in the acquisition of 100% of the shares of ADL Biopharma.

The team was led by **Luis Miguel de Dios** (partner), **Elena Alcázar** (counsel), **Aleksandra Czajka** (senior associate) and **Saphira Mouyazek** (associate).

ADL Biopharma is a company from Leon, dedicated to the manufacture, transformation, purchase and sale and distribution of chemical, chemical-pharmaceutical, pharmaceutical, para-pharmaceutical, cosmetic and food additives products.

Wacker will continue and expand existing relationships with ADL BioPharma's customers as a contract manufacturer (CMO) of fermentation manufactured products for the food, pharmaceutical and consumer goods industries.

The amount of the transaction exceeded 100 million euros. With this acquisition, Wacker strengthens its biotechnology business.